Cara Therapeutics, Inc. (NASDAQ:CARA) Given a $25.00 Price Target by Canaccord Genuity Analysts
Canaccord Genuity set a $25.00 target price on Cara Therapeutics, Inc. (NASDAQ:CARA) in a research note released on Saturday. The firm currently has a buy rating on the biopharmaceutical company’s stock.
CARA has been the topic of several other reports. Stifel Nicolaus reaffirmed a buy rating and issued a $20.00 price target (down from $24.00) on shares of Cara Therapeutics in a research report on Friday, June 23rd. Vetr raised Cara Therapeutics from a buy rating to a strong-buy rating and set a $22.99 price target on the stock in a research report on Tuesday, July 4th. HC Wainwright reaffirmed a buy rating and issued a $30.00 price target on shares of Cara Therapeutics in a research report on Monday, April 24th. Raymond James Financial, Inc. dropped their price target on Cara Therapeutics from $28.00 to $25.00 and set a market perform rating on the stock in a research report on Thursday, August 3rd. Finally, Zacks Investment Research raised Cara Therapeutics from a sell rating to a hold rating in a research report on Wednesday, May 10th. Five analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of Buy and an average price target of $25.18.
Cara Therapeutics (NASDAQ:CARA) opened at 14.36 on Friday. The firm has a 50-day moving average price of $16.62 and a 200-day moving average price of $16.30. The stock’s market cap is $466.80 million. Cara Therapeutics has a 12-month low of $5.27 and a 12-month high of $28.50.
Cara Therapeutics (NASDAQ:CARA) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.61) by $0.32. The business’s revenue was down 100.0% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.48) earnings per share. Analysts forecast that Cara Therapeutics will post ($1.78) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This story was first published by Daily Political and is owned by of Daily Political. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.dailypolitical.com/2017/08/09/cara-therapeutics-inc-nasdaqcara-given-a-25-00-price-target-by-canaccord-genuity-analysts.html.
In related news, VP Frederique Ph.D. Menzaghi sold 3,000 shares of the business’s stock in a transaction on Friday, July 14th. The stock was sold at an average price of $15.00, for a total value of $45,000.00. Following the sale, the vice president now owns 120,000 shares of the company’s stock, valued at approximately $1,800,000. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Derek T. Chalmers sold 25,000 shares of the business’s stock in a transaction on Friday, July 14th. The shares were sold at an average price of $15.05, for a total value of $376,250.00. Following the completion of the sale, the chief executive officer now directly owns 1,107,292 shares in the company, valued at approximately $16,664,744.60. The disclosure for this sale can be found here. Insiders have sold a total of 278,000 shares of company stock worth $6,888,750 in the last three months. 7.50% of the stock is owned by insiders.
A number of hedge funds have recently made changes to their positions in CARA. Russell Investments Group Ltd. bought a new stake in shares of Cara Therapeutics during the fourth quarter valued at approximately $404,000. State Street Corp raised its stake in shares of Cara Therapeutics by 7.1% in the fourth quarter. State Street Corp now owns 348,531 shares of the biopharmaceutical company’s stock valued at $3,244,000 after buying an additional 23,222 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Cara Therapeutics by 37.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 229,626 shares of the biopharmaceutical company’s stock valued at $2,133,000 after buying an additional 62,518 shares in the last quarter. FMR LLC bought a new stake in shares of Cara Therapeutics during the fourth quarter valued at approximately $845,000. Finally, Teachers Advisors LLC raised its stake in shares of Cara Therapeutics by 8.3% in the fourth quarter. Teachers Advisors LLC now owns 33,390 shares of the biopharmaceutical company’s stock valued at $310,000 after buying an additional 2,552 shares in the last quarter. 52.75% of the stock is currently owned by institutional investors and hedge funds.
About Cara Therapeutics
Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.
Receive News & Ratings for Cara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.